Cargando…

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40

INTRODUCTION: Continuous measures of amyloid burden as measured by positron emission tomography (PET) are being used increasingly to stage Alzheimer's disease (AD). This study examined whether cerebrospinal fluid (CSF) and plasma amyloid beta (Aβ)42/Aβ40 could predict continuous values for amyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wisch, Julie K., Gordon, Brian A., Boerwinkle, Anna H., Luckett, Patrick H., Bollinger, James G., Ovod, Vitaliy, Li, Yan, Henson, Rachel L., West, Tim, Meyer, Mathew R., Kirmess, Kristopher M., Benzinger, Tammie L.S., Fagan, Anne M., Morris, John C., Bateman, Randall J., Ances, Beau M., Schindler, Suzanne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980305/ https://www.ncbi.nlm.nih.gov/pubmed/36874595 http://dx.doi.org/10.1002/dad2.12405

Ejemplares similares

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
por: Delrieu, Julien, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
por: Brier, Matthew R., et al.
Publicado: (2016)

Comparison of plasma and CSF biomarkers in predicting cognitive decline
por: Aschenbrenner, Andrew J., et al.
Publicado: (2022)

Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
por: Elbert, Donald L., et al.
Publicado: (2022)

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol
por: Bollinger, Rebecca M, et al.
Publicado: (2021)

Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage
por: Meeker, Karin L., et al.
Publicado: (2022)

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
por: Schindler, Suzanne E., et al.
Publicado: (2021)

Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System
por: Dobrowolska, Justyna A., et al.
Publicado: (2014)

Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
por: Millar, Peter R, et al.
Publicado: (2023)

11 Clinical Manifestations of Neuroaxonal Injury
por: Keleman, Audrey A., et al.
Publicado: (2023)

Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
por: Gordon, Brian A., et al.
Publicado: (2018)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

Reduced CSF turnover and decreased ventricular Aβ42 levels are related
por: Serot, Jean-Marie, et al.
Publicado: (2011)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
por: West, Tim, et al.
Publicado: (2021)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Precipitating Mechanisms of Falls in Preclinical Alzheimer’s Disease
por: Keleman, Audrey A., et al.
Publicado: (2023)

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease
por: Wang, Qing, et al.
Publicado: (2019)

Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease
por: Roe, Catherine M., et al.
Publicado: (2018)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
por: Chen, Charles D., et al.
Publicado: (2023)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sr2el8pmnkgeh1fv82kt6u5l8n